Ferrous iron formation following the co-aggregation of ferric iron and the Alzheimer's disease peptide β-amyloid (1-42)

Journal of the Royal Society Interface

Volumn 11, Issue 95, 2014, Pages

  Everett, J ^a   Cespedes E ^a   Shelford, L R ^b   Exley, C ^c   Collingwood, J F ^d   Dobson, J ^e   Van Der Laan, G ^f   Jenkins, C A ^g   Arenholz, E ^g   Telling, N D ^a  

^a KEELE UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF EXETER   (United Kingdom)

^c KEELE UNIVERSITY   (United Kingdom)

^d UNIVERSITY OF WARWICK   (United Kingdom)

^e University of Florida   (United States)

^f DIAMOND LIGHT SOURCE LTD   (United Kingdom)

^g LAWRENCE BERKELEY NATIONAL LABORATORY   (United States)

Author keywords

Alzheimer's disease; Redox; W stite; X ray absorption; amyloid

Indexed keywords

DISEASE CONTROL; GLYCOPROTEINS; IRON COMPOUNDS; NEURODEGENERATIVE DISEASES; PEPTIDES; X RAY ABSORPTION SPECTROSCOPY;

ALZHEIMER'S DISEASE; ALZHEIMER'S DISEASE PATHOLOGIES; IRON CONCENTRATIONS; REDOX; REDOX-ACTIVE IRON; STRESS CHARACTERISTICS; SYNTHETIC IRON; X-RAY MICROSPECTROSCOPY;

IRON;

ALUMINUM; AMYLOID BETA PROTEIN[1-42]; FERROUS ION; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); IRON; PEPTIDE FRAGMENT;

ALZHEIMER DISEASE; ARTICLE; BRAIN DAMAGE; CONTROLLED STUDY; ELECTRON MICROSCOPY; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PROTEIN AGGREGATION; PROTEIN INTERACTION; PROTEIN STRUCTURE; QUANTITATIVE ANALYSIS; ROENTGEN SPECTROSCOPY; SPECTROPHOTOMETRY; X RAY ABSORPTION SPECTROSCOPY; BRAIN; BRAIN LEVEL; CHEMISTRY; HUMAN; METABOLISM;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; BRAIN; BRAIN CHEMISTRY; FERROUS COMPOUNDS; HUMANS; IRON; OXIDATIVE STRESS; PEPTIDE FRAGMENTS;

EID: 84901455157     PISSN: 17425689     EISSN: 17425662     Source Type: Journal    
DOI: 10.1098/rsif.2014.0165     Document Type: Article

References (51)

1. Connor JR, Menzies SL, Burdo JR, Boyer PJ. 2001 Iron and iron management proteins in neurobiology. Pediatr. Neurol. 25, 118-129. (doi:10.1016/S0887- 8994(01)00303-4)
2. Munoz P, Humeres A. 2012 Iron deficiency on neuronal function. Biometals 25, 825-835. (doi:10.1007/s10534-012-9550-x)
3. Chasteen ND, Harrison PM. 1999 Mineralization in ferritin: an efficient means of iron storage. J. Struct. Biol. 126, 182-194. (doi:10.1006/jsbi.1999. 4118)
4. Bolt HM, Marchan R. 2010 Iron dysregulation: an important aspect in toxicology. Arch. Toxicol. 84, 823-824. (doi:10.1007/s00204-010-0610-0)
5. Ong WY, Farooqui AA. 2005 Iron, neuroinflammation, and Alzheimer's disease. J. Alzheimer's Dis. 8, 183-200. (Pubitemid 43227164)
6. Zecca L, Youdim MBH, Riederer P, Connor JR, Crichton RR. 2004 Iron, brain ageing and neurodegenerative disorders. Nat. Rev. Neurosci. 5, 863-873. (doi:10.1038/nrn1537)
7. Smith MA, Harris PLR, Sayre LM, Perry G. 1997 Iron accumulation in Alzheimer disease is a source of redox-generated free radicals. Proc. Natl Acad. Sci. USA 94, 9866-9868. (doi:10.1073/pnas.94.18.9866)
8. Smith DG, Cappai R, Barnham KJ. 2007 The redox chemistry of the Alzheimer's disease amyloid b peptide. Biochim. Biophys. Acta Biomembr. 1768, 1976-1990. (doi:10.1016/j.bbamem.2007.02.002)
9. Honda K, Casadesus G, Petersen RB, Perry G, Smith MA. 2004 Oxidative stress and redox-active iron in Alzheimer's disease. Redox-Active Metals Neurol. Disord. 1012, 179-182. (Pubitemid 38453525)
10. Honda K, Moreira PI, Liu Q, Siedlak SL, Zhu XW, Smith MA, Perry G. 2005 Redox active iron at the center of oxidative stress in Alzheimer disease. Lett. Drug Des. Disc. 2, 479-482. (doi:10.2174/1570180054771545)
11. Huang XD, Moir RD, Tanzi RE, Bush AI, Rogers JT. 2004 Redox-active metals, oxidative stress, and Alzheimer's disease pathology. Redox-Active Metals Neurol. Disord. 1012, 153-163. (Pubitemid 38453522)
12. Thompson PM et al. 2003 Dynamics of gray matter loss in Alzheimer's disease. J. Neurosci. 23, 994-1005. (Pubitemid 36206191)
13. Fox NC, Crum WR, Scahill RI, Stevens JM, Janssen JC, Rossor MN. 2001 Imaging of onset and progression of Alzheimer's disease with voxel-compression mapping of serial magnetic resonance images. Lancet 358, 201-205. (doi:10.1016/S0140-6736(01)05408-3)
14. Hardy JA, Higgins GA. 1992 Alzheimer's disease - the amyloid cascade hypothesis. Science 256, 184-185. (doi:10.1126/science.1566067)
15. Hardy J, Selkoe DJ. 2002 Medicine-the amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297, 353-356. (doi:10.1126/science.1072994)
16. Fiala JC. 2007 Mechanisms of amyloid plaque pathogenesis. Acta Neuropathol. 114, 551-571. (doi:10.1007/s00401-007-0284-8)
17. Rogers J, Morrison JH. 1985 Quantitative morphology and regional and laminar distributions of senile plaques in Alzheimer's-disease. J. Neurosci. 5, 2801-2808. (Pubitemid 16232369)
18. Gotz J, Chen F, van Dorpe J, Nitsch RM. 2001 Formation of neurofibrillary tangles in P301L tau transgenic mice induced by Ab42 fibrils. Science 293, 1491-1495. (doi:10.1126/science.1062097)
19. Goedert M, Sisodia SS, Price DL. 1991 Neurofibrillary tangles and b-amyloid deposits in Alzheimer's disease. Curr. Opin. Neurobiol. 1, 441-447. (doi:10.1016/0959-4388(91)90067-H)
20. Butterfield DA, Boyd-Kimball D. 2005 The critical role of methionine 35 in Alzheimer's amyloid b-peptide (1-42)-induced oxidative stress and neurotoxicity. Biochim. Biophys. Acta Proteins Proteomics 1703, 149-156. (doi:10.1016/j.bbapap.2004.10.014)
21. Monji A, Utsumi H, Ueda T, Imoto T, Yoshida I, Hashioka S, Tashiro K, Tashiro N. 2001 The relationship between the aggregational state of the amyloid-b peptides and free radical generation by the peptides. J. Neurochem. 77, 1425-1432. (doi:10.1046/j.1471-4159.2001.00392.x)
22. Goodman L. 1953 Alzheimer's disease; a clinicopathologic analysis of twenty-three cases with a theory on pathogenesis. J. Nervous Mental Dis. 118, 97-130. (doi:10.1097/00005053-195308000-00001)
23. Deibel MA, Ehmann WD, Markesbery WR. 1996 Copper, iron, and zinc imbalances in severely degenerated brain regions in Alzheimer's disease: possible relation to oxidative stress. J. Neurol. Sci. 143, 137-142. (doi:10.1016/S0022-510X(96)00203-1)
24. Lovell MA, Robertson JD, Teesdale WJ, Campbell JL, Markesbery WR. 1998 Copper, iron and zinc in Alzheimer's disease senile plaques. J. Neurol. Sci. 158, 47-52. (doi:10.1016/S0022-510X(98)00092-6)
25. Dobson J. 2004 Magnetic iron compounds in neurological disorders. Redox-Active Metals Neurol. Disord. 1012, 183-192. (Pubitemid 38453526)
26. Hautot D, Pankhurst QA, Khan N, Dobson J. 2003 Preliminary evaluation of nanoscale biogenic magnetite in Alzheimer's disease brain tissue. Proc. R. Soc. B 270, S62-S64. (doi:10.1098/rsbl.2003.0012)
27. Quintana C, Cowley JM, Marhic C. 2004 Electron nanodiffraction and high-resolution electron microscopy studies of the structure and composition of physiological and pathological ferritin. J. Struct. Biol. 147, 166-178. (doi:10.1016/j.jsb.2004.03.001)
28. Pankhurst Q, Hautot D, Khan N, Dobson J. 2008 Increased levels of magnetic iron compounds in Alzheimer's disease. J. Alzheimer's Dis. 13, 49-52. (Pubitemid 351365627)
29. Collingwood JF et al. 2008 Three-dimensional tomographic imaging and characterization of iron compounds within Alzheimer's plaque core material. J. Alzheimer's Dis. 14, 235-245. (Pubitemid 352040039)
30. Collingwood JF, Mikhaylova A, Davidson M, Batich C, Streit WJ, Terry J, Dobson J. 2005 In situ characterization and mapping of iron compounds in Alzheimer's disease tissue. J. Alzheimer's Dis. 7, 267-272. (Pubitemid 41206937)
31. Collingwood J, Dobson J. 2006 Mapping and characterization of iron compounds in Alzheimer's tissue. J. Alzheimer's Dis. 10, 215-222. (Pubitemid 44763994)
32. Wu J, Ding T, Sun J. 2013 Neurotoxic potential of iron oxide nanoparticles in the rat brain striatum and hippocampus. Neurotoxicology 34, 243-253. (doi:10.1016/j.neuro.2012.09.006)
33. Nunomura A et al. 2001 Oxidative damage is the earliest event in Alzheimer disease. J. Neuropathol. Exp. Neurol. 60, 759-767. (Pubitemid 32678256)
34. Kell DB. 2009 Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases. BMC Med. Genomics 8, 2. (doi:10.1186/1755-8794-2-2)
35. Jiang D, Li X, Williams R, Patel S, Men L, Wang Y, Feimeng Z. 2009 Ternary complexes of iron, amyloid-β, and nitrilotriacetic acid: binding affinities, redox properties, and relevance to iron-induced oxidative stress in Alzheimer's disease. Biochemistry 48, 7939-7947. (doi:10.1021/bi900907a)
36. 42. Free Rad. Biol. Med. 40, 557-569. (doi:10.1016/j. freeradbiomed.2005.09.013)
37. Exley C, House E, Polwart A, Esiri MM. 2012 Brain burdens of aluminum, iron, and copper and their relationships with amyloid-b pathology in 60 human brains. J. Alzheimer's Dis. 31, 725-730.
38. House E, Esiri M, Forster G, Ince PG, Exley C. 2012 Aluminium, iron and copper in human brain tissues donated to the Medical Research Council's cognitive function and ageing study. Metallomics 4, 56-65. (doi:10.1039/ c1mt00139f)
39. Stookey LL. 1970 Ferrozine - a new spectrophotometric reagent for iron. Anal. Chem. 42, 779-782. (doi:10.1021/ac60289a016)
40. Stewart-Ornstein J, Hitchcock AP, Cruz DH, Henklein P, Overhage J, Hilpert K, Hale JD, Hancock REW. 2007 Using intrinsic X-ray absorption spectral differences to identify and map peptides and proteins. J. Phys. Chem. B 111, 7691-7699. (doi:10.1021/jp0720993)
41. Pearce CI, Henderson CMB, Telling ND, Pattrick RAD, Charnock JM, Coker VS, Arenholz E, Tuna F, van der Laan G. 2010 Fe site occupancy in magnetite-ulvospinel solid solutions: a new approach using X-ray magnetic circular dichroism. Am. Mineral. 95, 425-439. (doi:10.2138/am.2010.3343)
42. Coker VS, Gault AG, Pearce CI, van der Laan G, Telling ND, Charnock JM, Polya DA, Lloyd JR. 2006 XAS and XMCD evidence for species-dependent partitioning of arsenic during microbial reduction of ferrihydrite to magnetite. Environ. Sci. Technol. 40, 7745-7750. (doi:10.1021/es060990+)
43. Bush AI. 2003 The metallobiology of Alzheimer's disease. Trends Neurosci. 26, 207-214. (doi:10.1016/S0166-2236(03)00067-5)
44. Meadowcroft MD, Connor JR, Smith MB, Yang QX. 2009 MRI and histological analysis of beta-amyloid plaques in both human Alzheimer's disease and APP/PS1 transgenic mice. J. Magn. Reson. Imaging 29, 997-1007. (doi:10.1002/jmri.21731)
45. Gallagher JJ, Finnegan ME, Grehan B, Dobson J, Collingwood JF, Lynch MA. 2012 Modest amyloid deposition is associated with iron dysregulation, microglial activation, and oxidative stress. J. Alzheimer's Dis. 28, 147-161.
46. Everett J et al. In press. Evidence of redox-active iron formation following aggregation of ferrihydrite and the Alzheimer's disease peptide β-amyloid. Inorg. Chem. (doi:10.1021/ic402406g)
47. Ruiperez F, Mujika JJ, Ugalde JM, Exley C, Lopez X. 2012 Pro-oxidant activity of aluminum: promoting the Fenton reaction by reducing Fe(III) to Fe(II). J. Inorg. Biochem. 117, 118-123. (doi:10.1016/j.jinorgbio.2012.09.008)
48. Exley C. 1999 A molecular mechanism of aluminium-induced Alzheimer's disease? J. Inorg. Biochem. 76, 133-140. (doi:10.1016/S0162-0134(99)00125-7)
49. Wang XS, Ong WY, Connor JR. 2002 Increase in ferric and ferrous iron in the rat hippocampus with time after kainate-induced excitotoxic injury. Exp. Brain Res. 143, 137-148. (doi:10.1007/s00221-001-0971-y)
50. Quintana C, Bellefqih S, Laval JY, Guerquin-Kern JL, Wu TD, Avila J, Ferrer I, Arranz R, Patino C. 2006 Study of the localization of iron, ferritin, and hemosiderin in Alzheimer's disease hippocampus by analytical microscopy at the subcellular level. J. Struct. Biol. 153, 42-54. (doi:10.1016/j.jsb.2005.11. 001)
51. Exley C, House ER. 2011 Aluminium in the human brain. Monatshefte Chem. 142, 357-363. (doi:10.1007/s00706-010-0417-y)